Home » Topics » BioWorld Science

BioWorld Science
RSS

CPI-613 advances into phase II evaluation in biliary tract cancer

Aug. 26, 2021

New phase I/II trial investigates RVU-120 in relapsed/refractory metastatic or advanced solid tumors

Aug. 26, 2021

HUTCHMED begins phase Ib/II study of fruquintinib with tislelizumab in TNBC and endometrial cancer

Aug. 26, 2021

Janssen targets DHODH with new compounds for acute myelogenous leukemia

Aug. 26, 2021

Data presented for Almirall's JAK inhibitor LAS-200019

Aug. 26, 2021

Blade receives IND clearance for phase I study of cudetaxestat for IPF

Aug. 26, 2021

Mutational profiling gives clues to development, new puzzles about disease

Aug. 26, 2021

Memorial Sloan-Kettering Cancer Center describes prodrugs useful in adoptive cell therapy

Aug. 26, 2021

New CREB-2 inhibitors discovered at Evotec International

Aug. 26, 2021

Vertex Pharmaceuticals presents new apolipoprotein L1 inhibitors

Aug. 26, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...